digoxin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 882 | 20830-75-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | O |
| 0.25 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.99 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 60 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 4.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.70 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 38 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 24, 1975 | FDA | EUROHLTH INTL SARL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 2429.87 | 58.99 | 603 | 1777 | 32151 | 2323554 |
| Bradycardia | 1556.85 | 58.99 | 340 | 2040 | 9641 | 2346064 |
| Cardioactive drug level increased | 1348.09 | 58.99 | 184 | 2196 | 149 | 2355556 |
| Nausea | 644.95 | 58.99 | 308 | 2072 | 111881 | 2243824 |
| Acute kidney injury | 631.35 | 58.99 | 208 | 2172 | 27914 | 2327791 |
| Atrial fibrillation | 528.44 | 58.99 | 154 | 2226 | 13614 | 2342091 |
| Vomiting | 512.50 | 58.99 | 230 | 2150 | 71372 | 2284333 |
| Hyperkalaemia | 467.09 | 58.99 | 117 | 2263 | 5776 | 2349929 |
| Product complaint | 445.22 | 58.99 | 107 | 2273 | 4431 | 2351274 |
| Drug interaction | 444.69 | 58.99 | 162 | 2218 | 29001 | 2326704 |
| Dizziness | 442.77 | 58.99 | 196 | 2184 | 58469 | 2297236 |
| Asthenia | 403.06 | 58.99 | 172 | 2208 | 46754 | 2308951 |
| Hypotension | 398.91 | 58.99 | 154 | 2226 | 32282 | 2323423 |
| Decreased appetite | 301.34 | 58.99 | 122 | 2258 | 28769 | 2326936 |
| Overdose | 292.76 | 58.99 | 108 | 2272 | 19799 | 2335906 |
| Drug level increased | 264.03 | 58.99 | 64 | 2316 | 2723 | 2352982 |
| Ventricular tachycardia | 259.11 | 58.99 | 64 | 2316 | 2947 | 2352758 |
| International normalised ratio increased | 253.78 | 58.99 | 76 | 2304 | 7260 | 2348445 |
| Heart rate decreased | 251.30 | 58.99 | 65 | 2315 | 3611 | 2352094 |
| Atrioventricular block | 240.80 | 58.99 | 51 | 2329 | 1166 | 2354539 |
| Renal failure | 239.70 | 58.99 | 90 | 2290 | 17259 | 2338446 |
| Atrioventricular block complete | 238.77 | 58.99 | 52 | 2328 | 1362 | 2354343 |
| Dehydration | 238.42 | 58.99 | 96 | 2284 | 22199 | 2333506 |
| Confusional state | 226.88 | 58.99 | 95 | 2285 | 24249 | 2331456 |
| Diarrhoea | 220.97 | 58.99 | 139 | 2241 | 83425 | 2272280 |
| Cardiac failure | 216.43 | 58.99 | 76 | 2304 | 12018 | 2343687 |
| Dyspnoea | 198.03 | 58.99 | 127 | 2253 | 78606 | 2277099 |
| Cardiac arrest | 193.56 | 58.99 | 74 | 2306 | 14856 | 2340849 |
| Torsade de pointes | 189.39 | 58.99 | 47 | 2333 | 2199 | 2353506 |
| Cardioactive drug level above therapeutic | 187.33 | 58.99 | 25 | 2355 | 12 | 2355693 |
| Electrocardiogram QT prolonged | 186.50 | 58.99 | 61 | 2319 | 7753 | 2347952 |
| Fatigue | 179.67 | 58.99 | 123 | 2257 | 84750 | 2270955 |
| Atrioventricular block second degree | 178.41 | 58.99 | 36 | 2344 | 641 | 2355064 |
| Sinus bradycardia | 177.00 | 58.99 | 44 | 2336 | 2072 | 2353633 |
| Maternal exposure during pregnancy | 172.50 | 58.99 | 68 | 2312 | 14795 | 2340910 |
| Blood creatinine increased | 168.65 | 58.99 | 61 | 2319 | 10472 | 2345233 |
| Syncope | 164.14 | 58.99 | 68 | 2312 | 16807 | 2338898 |
| Nodal rhythm | 160.31 | 58.99 | 30 | 2350 | 352 | 2355353 |
| Visual impairment | 154.87 | 58.99 | 59 | 2321 | 11696 | 2344009 |
| Blood potassium increased | 145.88 | 58.99 | 38 | 2342 | 2158 | 2353547 |
| Metabolic acidosis | 143.73 | 58.99 | 47 | 2333 | 5951 | 2349754 |
| Arrhythmia | 143.50 | 58.99 | 47 | 2333 | 5981 | 2349724 |
| Bradyarrhythmia | 142.43 | 58.99 | 27 | 2353 | 341 | 2355364 |
| Atrioventricular block first degree | 137.97 | 58.99 | 31 | 2349 | 936 | 2354769 |
| Vision blurred | 135.46 | 58.99 | 57 | 2323 | 14611 | 2341094 |
| Condition aggravated | 133.85 | 58.99 | 72 | 2308 | 31907 | 2323798 |
| Multiple organ dysfunction syndrome | 132.58 | 58.99 | 47 | 2333 | 7594 | 2348111 |
| Fall | 125.33 | 58.99 | 79 | 2301 | 47020 | 2308685 |
| Hypokalaemia | 117.37 | 58.99 | 47 | 2333 | 10607 | 2345098 |
| Ventricular extrasystoles | 116.11 | 58.99 | 31 | 2349 | 1935 | 2353770 |
| Lethargy | 115.54 | 58.99 | 44 | 2336 | 8686 | 2347019 |
| Toxic epidermal necrolysis | 114.68 | 58.99 | 34 | 2346 | 3110 | 2352595 |
| Electrolyte imbalance | 110.32 | 58.99 | 30 | 2350 | 2007 | 2353698 |
| Ventricular fibrillation | 103.44 | 58.99 | 29 | 2351 | 2172 | 2353533 |
| Cardiogenic shock | 99.89 | 58.99 | 29 | 2351 | 2462 | 2353243 |
| Adverse drug reaction | 99.79 | 58.99 | 39 | 2341 | 8244 | 2347461 |
| Completed suicide | 98.16 | 58.99 | 51 | 2329 | 20983 | 2334722 |
| Sinus node dysfunction | 97.62 | 58.99 | 22 | 2358 | 672 | 2355033 |
| Malaise | 97.24 | 58.99 | 72 | 2308 | 55513 | 2300192 |
| Hyperthyroidism | 95.68 | 58.99 | 27 | 2353 | 2070 | 2353635 |
| Nodal arrhythmia | 94.51 | 58.99 | 18 | 2362 | 233 | 2355472 |
| Hyponatraemia | 91.24 | 58.99 | 42 | 2338 | 13283 | 2342422 |
| Bundle branch block right | 87.97 | 58.99 | 21 | 2359 | 829 | 2354876 |
| Abdominal pain | 87.11 | 58.99 | 56 | 2324 | 34318 | 2321387 |
| Respiratory disorder | 86.34 | 58.99 | 29 | 2351 | 3975 | 2351730 |
| Foetal exposure during pregnancy | 86.10 | 58.99 | 31 | 2349 | 5221 | 2350484 |
| Loss of consciousness | 86.09 | 58.99 | 45 | 2335 | 18722 | 2336983 |
| Blood pressure decreased | 85.51 | 58.99 | 36 | 2344 | 9200 | 2346505 |
| Cholecystitis | 85.05 | 58.99 | 25 | 2355 | 2215 | 2353490 |
| Medication error | 85.04 | 58.99 | 32 | 2348 | 6099 | 2349606 |
| Weight decreased | 83.90 | 58.99 | 51 | 2329 | 28320 | 2327385 |
| Heart rate increased | 82.31 | 58.99 | 37 | 2343 | 11068 | 2344637 |
| Premature delivery | 80.33 | 58.99 | 26 | 2354 | 3174 | 2352531 |
| Palpitations | 79.89 | 58.99 | 41 | 2339 | 16415 | 2339290 |
| Presyncope | 79.85 | 58.99 | 27 | 2353 | 3776 | 2351929 |
| Somnolence | 79.30 | 58.99 | 46 | 2334 | 23439 | 2332266 |
| Renal impairment | 79.19 | 58.99 | 35 | 2345 | 10057 | 2345648 |
| Exposure during pregnancy | 78.86 | 58.99 | 47 | 2333 | 25172 | 2330533 |
| Electrocardiogram abnormal | 78.36 | 58.99 | 21 | 2359 | 1327 | 2354378 |
| Electrocardiogram QRS complex prolonged | 77.65 | 58.99 | 20 | 2360 | 1082 | 2354623 |
| Tachyarrhythmia | 77.60 | 58.99 | 18 | 2362 | 626 | 2355079 |
| Mental status changes | 76.92 | 58.99 | 29 | 2351 | 5553 | 2350152 |
| Dermatitis exfoliative | 75.29 | 58.99 | 20 | 2360 | 1221 | 2354484 |
| Electrocardiogram ST segment depression | 74.03 | 58.99 | 17 | 2363 | 565 | 2355140 |
| Atrial flutter | 70.93 | 58.99 | 19 | 2361 | 1198 | 2354507 |
| Atrial tachycardia | 70.50 | 58.99 | 15 | 2365 | 348 | 2355357 |
| Supraventricular extrasystoles | 70.06 | 58.99 | 17 | 2363 | 719 | 2354986 |
| Blood urea increased | 69.45 | 58.99 | 24 | 2356 | 3581 | 2352124 |
| Subarachnoid haemorrhage | 69.15 | 58.99 | 21 | 2359 | 2079 | 2353626 |
| Drug ineffective | 68.47 | 58.99 | 77 | 2303 | 101547 | 2254158 |
| General physical health deterioration | 67.95 | 58.99 | 35 | 2345 | 14104 | 2341601 |
| Delirium | 67.87 | 58.99 | 26 | 2354 | 5197 | 2350508 |
| Xanthopsia | 67.69 | 58.99 | 11 | 2369 | 51 | 2355654 |
| Orthopnoea | 66.95 | 58.99 | 16 | 2364 | 634 | 2355071 |
| Cardiac failure congestive | 66.44 | 58.99 | 36 | 2344 | 16065 | 2339640 |
| Death | 65.84 | 58.99 | 68 | 2312 | 81400 | 2274305 |
| Bundle branch block left | 65.16 | 58.99 | 17 | 2363 | 967 | 2354738 |
| Left atrial dilatation | 63.27 | 58.99 | 13 | 2367 | 253 | 2355452 |
| Supraventricular tachycardia | 61.51 | 58.99 | 19 | 2361 | 1990 | 2353715 |
| Incorrect dose administered | 61.48 | 58.99 | 29 | 2351 | 9666 | 2346039 |
| Left ventricular dysfunction | 61.27 | 58.99 | 17 | 2363 | 1223 | 2354482 |
| Hallucination | 59.87 | 58.99 | 27 | 2353 | 8121 | 2347584 |
| Disorientation | 59.49 | 58.99 | 25 | 2355 | 6347 | 2349358 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 1877.52 | 51.43 | 522 | 1630 | 28619 | 1716010 |
| Bradycardia | 1822.13 | 51.43 | 418 | 1734 | 10116 | 1734513 |
| Cardioactive drug level increased | 957.54 | 51.43 | 139 | 2013 | 120 | 1744509 |
| Dizziness | 566.11 | 51.43 | 224 | 1928 | 34137 | 1710492 |
| Atrial fibrillation | 518.15 | 51.43 | 170 | 1982 | 14941 | 1729688 |
| Acute kidney injury | 485.94 | 51.43 | 202 | 1950 | 34742 | 1709887 |
| Hypotension | 447.54 | 51.43 | 182 | 1970 | 29472 | 1715157 |
| Hyperkalaemia | 442.35 | 51.43 | 132 | 2020 | 8415 | 1736214 |
| Nausea | 421.00 | 51.43 | 205 | 1947 | 50991 | 1693638 |
| Product complaint | 392.23 | 51.43 | 93 | 2059 | 2397 | 1742232 |
| Ventricular tachycardia | 343.63 | 51.43 | 91 | 2061 | 3707 | 1740922 |
| Vomiting | 321.14 | 51.43 | 156 | 1996 | 38159 | 1706470 |
| Drug interaction | 277.05 | 51.43 | 128 | 2024 | 27830 | 1716799 |
| Dyspnoea | 235.73 | 51.43 | 141 | 2011 | 51918 | 1692711 |
| Venous pressure jugular increased | 216.85 | 51.43 | 34 | 2118 | 69 | 1744560 |
| Fatigue | 215.41 | 51.43 | 132 | 2020 | 50649 | 1693980 |
| Cardiac murmur | 209.61 | 51.43 | 49 | 2103 | 1173 | 1743456 |
| Renal failure | 205.04 | 51.43 | 94 | 2058 | 19923 | 1724706 |
| Cardiac failure | 194.03 | 51.43 | 79 | 2073 | 12523 | 1732106 |
| Cardiac arrest | 192.39 | 51.43 | 84 | 2068 | 15846 | 1728783 |
| Asthenia | 191.14 | 51.43 | 107 | 2045 | 34563 | 1710066 |
| Atrioventricular block complete | 185.38 | 51.43 | 46 | 2106 | 1425 | 1743204 |
| Overdose | 185.35 | 51.43 | 83 | 2069 | 16618 | 1728011 |
| Decreased appetite | 183.31 | 51.43 | 92 | 2060 | 23779 | 1720850 |
| Confusional state | 175.13 | 51.43 | 86 | 2066 | 21192 | 1723437 |
| Syncope | 168.64 | 51.43 | 74 | 2078 | 14095 | 1730534 |
| Completed suicide | 164.90 | 51.43 | 76 | 2076 | 16236 | 1728393 |
| Atrioventricular block | 158.39 | 51.43 | 40 | 2112 | 1331 | 1743298 |
| Heart rate decreased | 155.89 | 51.43 | 46 | 2106 | 2763 | 1741866 |
| Drug level increased | 143.32 | 51.43 | 43 | 2109 | 2734 | 1741895 |
| Renal impairment | 132.55 | 51.43 | 60 | 2092 | 12254 | 1732375 |
| Cardioactive drug level above therapeutic | 130.27 | 51.43 | 18 | 2134 | 5 | 1744624 |
| Nodal rhythm | 127.65 | 51.43 | 26 | 2126 | 316 | 1744313 |
| Malaise | 124.93 | 51.43 | 77 | 2075 | 29488 | 1715141 |
| Left ventricular dysfunction | 123.50 | 51.43 | 32 | 2120 | 1179 | 1743450 |
| Oedema peripheral | 122.16 | 51.43 | 61 | 2091 | 15489 | 1729140 |
| Ventricular extrasystoles | 117.48 | 51.43 | 34 | 2118 | 1902 | 1742727 |
| Arrhythmia | 114.31 | 51.43 | 44 | 2108 | 5972 | 1738657 |
| Dehydration | 112.01 | 51.43 | 60 | 2092 | 17598 | 1727031 |
| Foetal exposure during pregnancy | 108.43 | 51.43 | 43 | 2109 | 6316 | 1738313 |
| Condition aggravated | 107.20 | 51.43 | 62 | 2090 | 21088 | 1723541 |
| Blood creatinine increased | 104.46 | 51.43 | 53 | 2099 | 13893 | 1730736 |
| International normalised ratio increased | 103.89 | 51.43 | 45 | 2107 | 8254 | 1736375 |
| Diarrhoea | 103.88 | 51.43 | 87 | 2065 | 53765 | 1690864 |
| General physical health deterioration | 98.65 | 51.43 | 50 | 2102 | 13068 | 1731561 |
| Vision blurred | 96.76 | 51.43 | 43 | 2109 | 8380 | 1736249 |
| Cardiac failure congestive | 94.28 | 51.43 | 51 | 2101 | 15219 | 1729410 |
| Atrial flutter | 91.26 | 51.43 | 28 | 2124 | 1914 | 1742715 |
| Heart rate irregular | 90.69 | 51.43 | 27 | 2125 | 1665 | 1742964 |
| Fall | 90.39 | 51.43 | 61 | 2091 | 27153 | 1717476 |
| Loss of consciousness | 89.93 | 51.43 | 49 | 2103 | 14826 | 1729803 |
| Atrioventricular block first degree | 87.06 | 51.43 | 23 | 2129 | 913 | 1743716 |
| Visual impairment | 85.31 | 51.43 | 36 | 2116 | 6182 | 1738447 |
| Dissociation | 85.21 | 51.43 | 18 | 2134 | 264 | 1744365 |
| Paraesthesia | 84.91 | 51.43 | 42 | 2110 | 10409 | 1734220 |
| Feeling abnormal | 82.27 | 51.43 | 42 | 2110 | 11124 | 1733505 |
| Ventricular fibrillation | 81.62 | 51.43 | 28 | 2124 | 2728 | 1741901 |
| Oedema | 81.47 | 51.43 | 36 | 2116 | 6912 | 1737717 |
| Dyspnoea exertional | 81.00 | 51.43 | 31 | 2121 | 4130 | 1740499 |
| Xanthopsia | 80.28 | 51.43 | 13 | 2139 | 35 | 1744594 |
| Blood potassium increased | 80.00 | 51.43 | 27 | 2125 | 2503 | 1742126 |
| Nodal arrhythmia | 78.94 | 51.43 | 16 | 2136 | 189 | 1744440 |
| Ventricular arrhythmia | 78.40 | 51.43 | 20 | 2132 | 690 | 1743939 |
| Drug ineffective | 78.02 | 51.43 | 80 | 2072 | 63721 | 1680908 |
| Palpitations | 75.70 | 51.43 | 34 | 2118 | 6780 | 1737849 |
| Adverse drug reaction | 70.24 | 51.43 | 29 | 2123 | 4709 | 1739920 |
| Electrocardiogram ST segment depression | 69.57 | 51.43 | 17 | 2135 | 490 | 1744139 |
| Cardiogenic shock | 69.05 | 51.43 | 24 | 2128 | 2430 | 1742199 |
| Premature baby | 68.49 | 51.43 | 25 | 2127 | 2917 | 1741712 |
| Blood urea increased | 67.01 | 51.43 | 28 | 2124 | 4683 | 1739946 |
| Lethargy | 64.69 | 51.43 | 31 | 2121 | 7153 | 1737476 |
| Abnormal loss of weight | 63.87 | 51.43 | 16 | 2136 | 512 | 1744117 |
| Ejection fraction decreased | 63.33 | 51.43 | 22 | 2130 | 2223 | 1742406 |
| Sinus bradycardia | 62.56 | 51.43 | 21 | 2131 | 1912 | 1742717 |
| Serotonin syndrome | 62.34 | 51.43 | 23 | 2129 | 2765 | 1741864 |
| Heart rate increased | 61.39 | 51.43 | 29 | 2123 | 6481 | 1738148 |
| Left ventricular failure | 59.39 | 51.43 | 16 | 2136 | 684 | 1743945 |
| Electrocardiogram abnormal | 59.14 | 51.43 | 18 | 2134 | 1195 | 1743434 |
| Bradyarrhythmia | 58.52 | 51.43 | 14 | 2138 | 368 | 1744261 |
| Tachycardia | 58.50 | 51.43 | 35 | 2117 | 12593 | 1732036 |
| Medication error | 56.93 | 51.43 | 25 | 2127 | 4718 | 1739911 |
| Bundle branch block left | 56.75 | 51.43 | 16 | 2136 | 811 | 1743818 |
| Atrial tachycardia | 56.29 | 51.43 | 13 | 2139 | 292 | 1744337 |
| Conduction disorder | 52.85 | 51.43 | 13 | 2139 | 385 | 1744244 |
| Seizure | 51.96 | 51.43 | 39 | 2113 | 20402 | 1724227 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01AA05 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC GLYCOSIDES Digitalis glycosides |
| FDA EPC | N0000175568 | Cardiac Glycoside |
| FDA CS | M0003451 | Cardiac Glycosides |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D020011 | Protective Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Poisoning by digitalis glycoside | indication | 12876009 | |
| Chronic heart failure | indication | 48447003 | |
| Atrial fibrillation | indication | 49436004 | DOID:0060224 |
| Senile cardiac amyloidosis | contraindication | 16573007 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
| Myxedema | contraindication | 43153006 | DOID:11634 |
| Hypokalemia | contraindication | 43339004 | |
| Sinus bradycardia | contraindication | 49710005 | |
| Myocarditis | contraindication | 50920009 | DOID:820 |
| Acute nephropathy | contraindication | 58574008 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Ventricular fibrillation | contraindication | 71908006 | |
| Wolff-Parkinson-White pattern | contraindication | 74390002 | DOID:384 |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Constrictive pericarditis | contraindication | 85598007 | DOID:11481 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hypomagnesemia | contraindication | 190855004 | |
| Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
| Idiopathic hypertrophic subaortic stenosis | contraindication | 360465008 | |
| Restrictive cardiomyopathy | contraindication | 415295002 | DOID:397 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.05MG/ML | DIGOXIN | VISTAPHARM | A213000 | Oct. 4, 2019 | RX | ELIXIR | ORAL | April 1, 2020 | COMPETITIVE GENERIC THERAPY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/potassium-transporting ATPase | Transporter | INHIBITOR | IC50 | 6.40 | CHEMBL | CHEMBL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.14 | WOMBAT-PK | |||||
| Signal transducer and activator of transcription 3 | Transcription factor | IC50 | 5.73 | CHEMBL | |||||
| Nuclear receptor ROR-gamma | Nuclear hormone receptor | IC50 | 5.70 | CHEMBL | |||||
| Sodium/potassium-transporting ATPase subunit alpha-1 | Transporter | IC50 | 6.30 | CHEMBL | |||||
| Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 5.78 | DRUG MATRIX | |||||
| Nuclear receptor ROR-gamma | Unclassified | IC50 | 5.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D004077 | MESH_DESCRIPTOR_UI |
| 4018047 | VUID |
| N0000146388 | NUI |
| C0012265 | UMLSCUI |
| D00298 | KEGG_DRUG |
| 73K4184T59 | UNII |
| 389 | INN_ID |
| 1413 | MMSL |
| 3407 | RXNORM |
| 387461009 | SNOMEDCT_US |
| 4597 | MMSL |
| d00210 | MMSL |
| 796001 | SNOMEDCT_US |
| 4018047 | VANDF |
| 000593 | NDDF |
| DB00390 | DRUGBANK_ID |
| CHEMBL1751 | ChEMBL_ID |
| DGX | PDB_CHEM_ID |
| CHEBI:145795 | CHEBI |
| 4726 | IUPHAR_LIGAND_ID |
| 2724385 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0057 | SOLUTION | 0.05 mg | ORAL | NDA | 17 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9811 | TABLET | 125 ug | ORAL | ANDA | 17 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9822 | TABLET | 250 ug | ORAL | ANDA | 17 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1240 | TABLET | 125 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-1241 | TABLET | 250 ug | ORAL | ANDA | 16 sections |
| DIGITEK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6155 | TABLET | 0.13 mg | ORAL | ANDA | 16 sections |
| DIGITEK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6156 | TABLET | 0.25 mg | ORAL | ANDA | 16 sections |
| DIGOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1324 | TABLET | 125 ug | ORAL | ANDA | 11 sections |
| DIGOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1325 | TABLET | 250 ug | ORAL | ANDA | 11 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-0518 | TABLET | 250 ug | ORAL | ANDA | 12 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-0547 | TABLET | 0.13 mg | ORAL | ANDA | 12 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7729 | TABLET | 125 ug | ORAL | ANDA | 11 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7730 | TABLET | 250 ug | ORAL | ANDA | 11 sections |
| DIGOXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7935 | TABLET | 0.13 mg | ORAL | NDA AUTHORIZED GENERIC | 17 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8202 | TABLET | 125 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-1410 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6184 | INJECTION | 0.25 mg | INTRAMUSCULAR | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3059 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5921 | TABLET | 125 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5922 | TABLET | 250 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6886 | TABLET | 125 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-590 | TABLET | 125 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-591 | TABLET | 250 ug | ORAL | ANDA | 16 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0057 | SOLUTION | 0.05 mg | ORAL | NDA | 15 sections |
| Digoxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-678 | TABLET | 0.13 mg | ORAL | ANDA | 17 sections |
| LANOXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24987-262 | INJECTION, SOLUTION | 100 ug | INTRAMUSCULAR | NDA | 11 sections |
| DIGITEK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42292-002 | TABLET | 0.25 mg | ORAL | ANDA | 16 sections |
| DIGITEK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42292-003 | TABLET | 0.13 mg | ORAL | ANDA | 16 sections |
| DIGOXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-494 | TABLET | 0.25 mg | ORAL | NDA AUTHORIZED GENERIC | 17 sections |
| DIGOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49999-181 | TABLET | 250 ug | ORAL | ANDA | 10 sections |